Artelo Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Artelo Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $27 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 94% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-14.0×Operating cash was negative last year, while some debt falls due within a year.
Higher than 51% of Healthcare companies in United States.
Cash Cushion Ratio
−6%Debt, after subtracting cash, equals 6% of its market value (net debt).
Lower than 75% of Healthcare companies in United States.
Tangible Assets Ratio
27%Of every $100 the company owns, $27 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 94% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Artelo Biosciences, Inc. made a loss over the last year. Artelo Biosciences, Inc. owes $0.23 for every $1 it owns. Artelo Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossArtelo Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.28The share price is 0.28 times Artelo Biosciences, Inc.'s book value per share, lower than 97% of Healthcare companies in United States.
Market cap
$1 MThe total market value of all of Artelo Biosciences, Inc.'s shares at today's price (share price × number of shares), smaller than almost all Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$5 MWhat Artelo Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$9.12Net worth divided by the number of shares. The share price of $2.55 is 0.3 times this, which is the P/B above.
Return on equity (ROE)
-705.7%Artelo Biosciences, Inc. lost 705.7% of its shareholders' money over the last year, lower than 96% of Healthcare companies in United States.
Owes vs Owns
0.23×Artelo Biosciences, Inc. owes $0.23 for every $1 it owns (low), lower than 70% of Healthcare companies in United States.
Dividend yield
NoneArtelo Biosciences, Inc. does not currently pay a dividend.
Profit growth
LossArtelo Biosciences, Inc. made a loss in each of the last two years.
Interest cover
Not coveredArtelo Biosciences, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtArtelo Biosciences, Inc. had $0 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Artelo Biosciences, Inc.: $1 M ÷ $5 M (30 Jun 2026) = 0.3.
What is Artelo Biosciences, Inc.'s return on equity?
Artelo Biosciences, Inc. lost 705.7% of its shareholders' money over the last year, lower than 96% of Healthcare companies in United States.
How much does Artelo Biosciences, Inc. owe compared with what it owns?
Artelo Biosciences, Inc. owes $0.23 for every $1 it owns (low), lower than 70% of Healthcare companies in United States.
Does Artelo Biosciences, Inc. pay a dividend?
No. Artelo Biosciences, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.